Central neurological manifestations during chemotherapy in children;Toxicité neurologique centrale des chimiothérapies: État des connaissances actuelles

Archives de Pediatrie

Volumn 10, Issue 6, 2003, Pages 533-539

  Orbach, D ^a   Brisse, H ^a   Doz, F ^a  

^a INSTITUT CURIE   (France)

Author keywords

Central nervous system; Chemotherapy; Child; Drug toxicity

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; ERWINIASE; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; PLATINUM DERIVATIVE; THIOTEPA; VINCRISTINE; VINCRISTINE SULFATE;

BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; HUMAN; MOTOR DYSFUNCTION; NEUROTOXICITY; REVIEW; SEIZURE;

EID: 0041667802     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00105-2     Document Type: Review

References (52)

1. Vassal G. Pharmacologic bases of chemotherapy of brain tumors in children. Bull Cancer 1990;77:699-713.
2. Castellanos AM, Fields WS. Grading of neurotoxicity in cancer therapy. J Clin Oncol 1986;4(1):277-8.
3. Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998;34:1050-62.
4. Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8:1399-401.
5. Canpolat C, Pearson P, Robertson R, Jaffe N. Ifosfamide tolerance in osteosarcoma patients previously treated with cisdiamminedichloroplatinum-II: renal, hematologic, and neurologic observations. Med Pediatr Oncol 1996;26:36-47.
6. Gieron MA, Barak LS, Estrada J. Severe encephalopathy associated with ifosfamide administration in 2 children with metastatic tumors. J Neurooncol 1988;6:29-30.
7. Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990;335:175.
8. Chastagner P, Sommelet-Olive D, Kalifa C, Brunat-Mentigny M, Zucker JM, Demeocq F, et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (Sfop). Med Pediatr Oncol 1993;21:49-53.
9. Bruggers CS, Friedman HS, Tien R, Delong R. Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol 1994; 23:380-3.
10. Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglass E, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4: 1253-61.
11. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249-52.
12. Dourthe LM, Coutant G, Desrame J, Merrer J, Daly JP. Ifosfamide-related encephalopathy. Report of 2 cases. Rev Med Interne 1999;20: 264-6.
13. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
14. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother 1992;26:30-1.
15. Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer 1992(Suppl 18): S36-40.
16. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69:203-7.
17. Packer RJ, Grossman RI, Belasco JB. High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 1983;11:159-61.
18. Allen JC, Rosen G, Mehta BM, Horten B. Leuko-encephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980;64:1261-73.
19. Mahoney DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. J Clin Oncol 1998; 16:1712-22.
20. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-3.
21. Bleyer AW. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977;61:1419-25.
22. Garcia-Tena J, Lopez-Andreu JA, Ferris J, Menor F, Mulas F, Millet E, et al. Intrathecal chemotherapy-related myelo-encephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1995;12:377-85.
23. Yim YS, Mahoney DH, Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-61.
24. Saiki JH, Thompson S, Smith F, Atkinson R. Paraplegia following intrathecal chemotherapy. Cancer 1972;29:370-4.
25. von der Weid NX, de Crousaz H, Beck D, Deonna T, Miklossy J, Janzer RC. Acute fatal myelo-encephalopathy after combined intrathecal chemotherapy in a child with acute lymphoblastic leukemia. Med Pediatr Oncol 1991;19:192-8.
26. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4: 1845-50.
27. Jaffe N, Takaue Y, Anzai T, Robertson R. Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985; 56:1356-60.
28. Kay HE, Knapton PJ, O'Sullivan JP, Wells DG, Harris RF, Innes EM, et al. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 1972;47:344-54.
29. Ginsberg LE, Leeds NE. Neuroradiology of leukemia. AJR Am J Roentgenol 1995;165:525-34.
30. Mueller S, Bell W, Seibert J. Cerebral calcifications associated with intrathecal methotrexate therapy in acute lymphocytic leukemia. J Pediatr 1976;88:650-3.
31. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35:291-305.
32. Wilson DA, Nitschke R, Bowman ME, Chaffin MJ, Sexauer CL, Prince JR. Transient white matter changes on MR images in children undergoing chemotherapy for acute lymphocytic leukemia: correlation with neuropsychologic deficiencies. Radiology 1991;180:205-9.
33. Brouwers P, Poplack D. Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: association with attention deficits. Am J Pediatr Hematol Oncol 1990;12:174-81.
34. Herzig RH, Lazarus HM, Herzig GP, Coccia PF, Wolff SN. Central nervous system toxicity with high-dose cytosine arabinoside. Semin Oncol 1985;12:233-6.
35. Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989;7: 1563-8.
36. Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992;10:948-53.
37. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997;15:833-9.
38. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9:679-93.
39. Barnett MJ, Richards MA, Ganesan TS, Waxman JH, Smith BF, Butler MG, et al. Central nervous system toxicity of high-dose cytosine arabinoside. Semin Oncol 1985;12:227-32.
40. Salinsky MC, Levine RL, Aubuchon JP, Schutta HS. Acute cerebellar dysfunction with high-dose Ara-C therapy. Cancer 1983;51:426-9.
41. Vera P, Rohrlich P, Stievenart JL, Elmaleh M, Duval M, Bonnin F, et al. Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia. J Clin Oncol 1999;17: 2804-10.
42. Lazarus HM. Acute cerebellar dysfunction with high-dose Ara-C therapy. Cancer 1984;53:17A.
43. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 1982; 100:990-5.
44. Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988;38:127-33.
45. Risseeuw-Appel IM, Dekker I, Hop WC, Hahlen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol 1994;23:335-43.
46. Priest JR, Ramsay NK, Latchaw RE, Lockman LA, Hasegawa DK, Coates TD, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980;46:1548-54.
47. Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr 1986;108:698-701.
48. Cairo MS, Lazarus K, Gilmore RL, Baehner RL. Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr 1980;97: 829-33.
49. Akman SA, Block JB. Neurologic complications of systemic cancer. Prim Care 1984;11:597-623.
50. Antunes NL. The spectrum of neurologic disease in children with systemic cancer. Pediatr Neurol 2001;25:227-35.
51. Kaste SC, Rodriguez-Galindo C, Furman WL, Langston J, Thompson SJ. Imaging aspects of neurologic emergencies in children treated for non-CNS malignancies. Pediatr Radiol 2000;30:558-65.
52. Lewis DW, Packer RJ, Raney B, Rak IW, Belasco J, Lange B. Incidence, presentation, and outcome of spinal cord disease in children with systemic cancer. Pediatrics 1986;78:438-43.